Activist Investor Demands Exelixis Cut R&D Spending And Learn From Peers

CEO Pushes Back On R&D Spending Cut Calls

 
• By Andrew McConaghie
  
Stock Index close up
The activist investors insist that greater focus on R&D spending and shareholder return will be good for business
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas